{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T23:58:04Z","timestamp":1780617484143,"version":"3.54.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,12]]},"DOI":"10.7759\/cureus.80461","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T12:17:57Z","timestamp":1741781877000},"source":"Crossref","is-referenced-by-count":1,"title":["Steroids Versus Immunomodulators in Cardiac Sarcoidosis: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Moiuz","family":"Chaudhri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Goodwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raviv","family":"Markovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Brancaccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Hammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Acquah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Okere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s12350-016-0658-1","article-title":"Isolated cardiac sarcoidosis: a focused review of an under-recognized entity","volume":"25","author":"Okada DR","year":"2018","unstructured":"Okada DR, Bravo PE, Vita T, et al.. Isolated cardiac sarcoidosis: a focused review of an under-recognized entity. J Nucl Cardiol. 2018, 25:1136-46. 10.1007\/s12350-016-0658-1","journal-title":"J Nucl Cardiol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.03.605","article-title":"Cardiac sarcoidosis","volume":"68","author":"Birnie DH","year":"2016","unstructured":"Birnie DH, Nery PB, Ha AC, Beanlands RS. Cardiac sarcoidosis. J Am Coll Cardiol. 2016, 68:411-21. 10.1016\/j.jacc.2016.03.605","journal-title":"J Am Coll Cardiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra071714","article-title":"Sarcoidosis","volume":"357","author":"Iannuzzi MC","year":"2007","unstructured":"Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007, 357:2153-65. 10.1056\/NEJMra071714","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9149(01)01978-6","article-title":"Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone","volume":"88","author":"Yazaki Y","year":"2001","unstructured":"Yazaki Y, Isobe M, Hiroe M, Sekiguchi M, Central Japan Heart Study Group. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol. 2001, 88:1006-40. 10.1016\/s0002-9149(01)01978-6","journal-title":"Am J Cardiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2021.06.016","article-title":"Sarcoidosis-related cardiomyopathy: current knowledge, challenges, and future perspectives state-of-the-art review","volume":"28","author":"Gilotra NA","year":"2022","unstructured":"Gilotra NA, Griffin JM, Pavlovic N, et al.. Sarcoidosis-related cardiomyopathy: current knowledge, challenges, and future perspectives state-of-the-art review. J Card Fail. 2022, 28:113-32. 10.1016\/j.cardfail.2021.06.016","journal-title":"J Card Fail"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1513\/pats.200606-130MS","article-title":"Role of CD4+ T cells in sarcoidosis","volume":"4","author":"Grunewald J","year":"2007","unstructured":"Grunewald J, Eklund A. Role of CD4+ T cells in sarcoidosis. Proc Am Thorac Soc. 2007, 4:461-4. 10.1513\/pats.200606-130MS","journal-title":"Proc Am Thorac Soc"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.08.042","article-title":"Challenges in cardiac and pulmonary\u00a0sarcoidosis: JACC state-of-the-art review","volume":"76","author":"Trivieri MG","year":"2020","unstructured":"Trivieri MG, Spagnolo P, Birnie D, et al.. Challenges in cardiac and pulmonary\u00a0sarcoidosis: JACC state-of-the-art review. J Am Coll Cardiol. 2020, 76:1878-901. 10.1016\/j.jacc.2020.08.042","journal-title":"J Am Coll Cardiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-015-8481-z","article-title":"Etiologies of sarcoidosis","volume":"49","author":"Chen ES","year":"2015","unstructured":"Chen ES, Moller DR. Etiologies of sarcoidosis. Clin Rev Allergy Immunol. 2015, 49:6-18. 10.1007\/s12016-015-8481-z","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/00063198-200209000-00014","article-title":"Epidemiology of sarcoidosis: new frontiers to explore","volume":"8","author":"Hosoda Y","year":"2002","unstructured":"Hosoda Y, Sasagawa S, Yasuda N. Epidemiology of sarcoidosis: new frontiers to explore. Curr Opin Pulm Med. 2002, 8:424-8. 10.1097\/00063198-200209000-00014","journal-title":"Curr Opin Pulm Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200402-249OC","article-title":"A case control etiologic study of sarcoidosis: environmental and occupational risk factors","volume":"170","author":"Newman LS","year":"2004","unstructured":"Newman LS, Rose CS, Bresnitz EA, et al.. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med. 2004, 170:1324-30. 10.1164\/rccm.200402-249OC","journal-title":"Am J Respir Crit Care Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2015-307877","article-title":"Diagnosis and treatment of cardiac sarcoidosis","volume":"102","author":"Kusano KF","year":"2016","unstructured":"Kusano KF, Satomi K. Diagnosis and treatment of cardiac sarcoidosis. Heart. 2016, 102:184-90. 10.1136\/heartjnl-2015-307877","journal-title":"Heart"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2013.09.004","article-title":"Effect of corticosteroid on arrhythmic events in patients with cardiac sarcoidosis","volume":"62","author":"Kusano KF","year":"2013","unstructured":"Kusano KF. Effect of corticosteroid on arrhythmic events in patients with cardiac sarcoidosis. J Cardiol. 2013, 62:326-7. 10.1016\/j.jjcc.2013.09.004","journal-title":"J Cardiol"},{"key":"ref13","unstructured":"IBM SPSS Statistics. https.\/\/www.ibm.com\/products\/spss-statistics\/var?adoper=265413_1&utm_content=SRCWW&p1=Search&p4=43700050715561164&p5=...."},{"key":"ref14","article-title":"GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations","year":"2013","unstructured":"GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations. Sch\u00fcnemann H, Bro\u017cek J, Guyatt G, Oxman A (ed). The GRADE Working Group, 2013."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2004.08.083","article-title":"Prevention of left ventricular remodeling by long-term corticosteroid therapy in patients with cardiac sarcoidosis","volume":"95","author":"Chiu CZ","year":"2005","unstructured":"Chiu CZ, Nakatani S, Zhang G, et al.. Prevention of left ventricular remodeling by long-term corticosteroid therapy in patients with cardiac sarcoidosis. Am J Cardiol. 2005, 95:143-6. 10.1016\/j.amjcard.2004.08.083","journal-title":"Am J Cardiol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2021.06.010","article-title":"Management of cardiac sarcoidosis using mycophenolate mofetil as a steroid-sparing agent","volume":"27","author":"Griffin JM","year":"2021","unstructured":"Griffin JM, Chasler J, Wand AL, et al.. Management of cardiac sarcoidosis using mycophenolate mofetil as a steroid-sparing agent. J Card Fail. 2021, 27:1348-58. 10.1016\/j.cardfail.2021.06.010","journal-title":"J Card Fail"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2021.02.022","article-title":"Effectiveness and safety of infliximab in cardiac sarcoidosis","volume":"330","author":"Bakker AL","year":"2021","unstructured":"Bakker AL, Mathijssen H, Azzahhafi J, et al.. Effectiveness and safety of infliximab in cardiac sarcoidosis. Int J Cardiol. 2021, 330:179-85. 10.1016\/j.ijcard.2021.02.022","journal-title":"Int J Cardiol"},{"key":"ref18","article-title":"Efficacy of corticosteroids in sarcoidosis presenting with atrioventricular block","volume":"20","author":"Kato Y","year":"2003","unstructured":"Kato Y, Morimoto S, Uemura A, Hiramitsu S, Ito T, Hishida H. Efficacy of corticosteroids in sarcoidosis presenting with atrioventricular block. Sarcoidosis Vasc Diffuse Lung Dis. 2003, 20:133-7.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s12350-022-03171-6","article-title":"Prednisone vs methotrexate in treatment na\u00efve cardiac sarcoidosis","volume":"30","author":"Vis R","year":"2023","unstructured":"Vis R, Mathijssen H, Keijsers RG, et al.. Prednisone vs methotrexate in treatment na\u00efve cardiac sarcoidosis. J Nucl Cardiol. 2023, 30:1543-53. 10.1007\/s12350-022-03171-6","journal-title":"J Nucl Cardiol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.53.0794","article-title":"Treatment with methotrexate and low-dose corticosteroids in sarcoidosis patients with cardiac lesions","volume":"53","author":"Nagai S","year":"2014","unstructured":"Nagai S, Yokomatsu T, Tanizawa K, et al.. Treatment with methotrexate and low-dose corticosteroids in sarcoidosis patients with cardiac lesions. Intern Med. 2014, 53:427-33. 10.2169\/internalmedicine.53.0794","journal-title":"Intern Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2019.07.067","article-title":"Infliximab for refractory cardiac sarcoidosis","volume":"124","author":"Harper LJ","year":"2019","unstructured":"Harper LJ, McCarthy M, Ribeiro Neto ML, et al.. Infliximab for refractory cardiac sarcoidosis. Am J Cardiol. 2019, 124:1630-5. 10.1016\/j.amjcard.2019.07.067","journal-title":"Am J Cardiol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcha.2024.101473","article-title":"Cardiac sarcoidosis treated with nonsteroidal immunosuppressive therapy","volume":"53","author":"Suwa K","year":"2024","unstructured":"Suwa K, Naruse Y, Nabeta T, et al.. Cardiac sarcoidosis treated with nonsteroidal immunosuppressive therapy. Int J Cardiol Heart Vasc. 2024, 53:101473. 10.1016\/j.ijcha.2024.101473","journal-title":"Int J Cardiol Heart Vasc"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2023.05.017","article-title":"Prospective analysis of immunosuppressive therapy in cardiac sarcoidosis with fluorodeoxyglucose myocardial accumulation: the PRESTIGE study","volume":"17","author":"Morimoto R","year":"2024","unstructured":"Morimoto R, Unno K, Fujita N, et al.. Prospective analysis of immunosuppressive therapy in cardiac sarcoidosis with fluorodeoxyglucose myocardial accumulation: the PRESTIGE study. JACC Cardiovasc Imaging. 2024, 17:45-58. 10.1016\/j.jcmg.2023.05.017","journal-title":"JACC Cardiovasc Imaging"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2021.07.008","article-title":"Rituximab for the treatment of refractory cardiac sarcoidosis: a single-center experience","volume":"28","author":"Elwazir M","year":"2022","unstructured":"Elwazir M, Krause ML, Bois JP, et al.. Rituximab for the treatment of refractory cardiac sarcoidosis: a single-center experience. J Card Fail. 2022, 28:247-58. 10.1016\/j.cardfail.2021.07.008","journal-title":"J Card Fail"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2022.04.051","article-title":"Effect of corticosteroids on left ventricular function in patients with cardiac sarcoidosis","volume":"177","author":"Wand AL","year":"2022","unstructured":"Wand AL, Pavlovic N, Duvall C, et al.. Effect of corticosteroids on left ventricular function in patients with cardiac sarcoidosis. Am J Cardiol. 2022, 177:108-15. 10.1016\/j.amjcard.2022.04.051","journal-title":"Am J Cardiol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/340803-steroids-versus-immunomodulators-in-cardiac-sarcoidosis-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T12:18:01Z","timestamp":1741781881000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/340803-steroids-versus-immunomodulators-in-cardiac-sarcoidosis-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.80461","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,12]]}}}